Scrip Awards 2019 Shortlist

We are delighted to announce the shortlist for the 15th Annual Scrip Awards.

View details of the shortlisted entries below or download the PDF here: 

Masters Speciality Pharma’s Best Company in an Emerging Market Award

Best Technological Development in Clinical Trials

Medidata’s Community Partnership of the Year Award

MSD’s Innovation Award

IQVIA’s Clinical Advance of the Year Award

Financing Deal of the Year

Worldwide Clinical Trials’ Licensing Deal of the Year Award

Best Partnership Alliance

Business Development Team of the Year

Executive of the Year - For Large & Medium Cap Companies

Executive of the Year - For Small Cap & Private Pharma Companies

Best Contract Research Organization – Full-Service Providers

Best Contract Research Organization – Specialist Providers

WuXi App Tec’s Biotech Company of the Year Award

Syneos Health’s Best New Drug Award


Masters Speciality Pharma’s Best Company in an Emerging Market Award

BeiGene

Cipla

Hikma Pharmaceuticals

Hutchison China MediTech

Mundipharma Singapore

WuXi AppTec

Best Technological Development in Clinical Trials

Antidote’s Match-technology driven program-level recruitment

Clinical Ink's eSource ecosystem

CluePoints' Risk-Based Study Execution and Data Quality Oversight Software for Clinical Trials

Exom Group’s Genius ROSA (Remote Omnichannel Study Assistance)

Saama Technologies’ Deep Learning Intelligent Assistant

Signant Health’s SmartSupplies suite

Tata Consultancy’s TCS Connected Clinical Trials platform

Medidata’s Community Partnership of the Year Award

AstraZeneca's Energy Challenge

IQVIA’s Light The Night Campaign

Merck KGaA’s Embracing Carers initiative

Regeneron Science Talent Search  

Roche/Chugai communications partnership with LADbible for The Haemophilia Society and Little Bleeders

MSD’s Innovation Award

Evonetix’s DNA synthesis platform

Invitrogen EVOS M7000 microscope

Kaleido's microbiome research platform

Mogrify’s direct cellular conversion technology

Lyndra Therapeutics’ ultra-long acting pill

NeuBase Therapeutics’ PATrOL platform

IQVIA’s Clinical Advance of the Year Award

Akcea Therapeutics/Ionis Pharmaceuticals’ Phase II study of AKCEA-APO(a)-LRx in cardiovascular disease

Alkermes’ ENLIGHTEN-2 Phase III study of ALKS 3831 for schizophrenia

Galapagos’ EQUATOR and TORTUGA trials of filgotinib in psoriatic arthritis and ankylosing spondylitis

National Cancer Institute-sponsored E1912 Phase III study of Imbruvica in chronic lymphocytic leukemia

Novartis/AveXis’ Phase III STR1VE study of Zolgensma in spinal muscular atrophy

Financing Deal of the Year

Allogene Therapeutics’ $372.6m IPO

Artios’s $84m series B financing

Cambridge Innovation Capital £150m funding round

Galapagos’s $345m secondary follow-on financing

iTeos Therapeutics’ $75m series B financing

Sensyne Health's £60m IPO

Worldwide Clinical Trials’ Licensing Deal of the Year Award

Agenus and Gilead Sciences for GS-1423 in immuno-oncology

AstraZeneca and Daiichi-Sankyo for trastuzumab deruxtecan in multiple tumor types

Innate Pharma and AstraZeneca’s five-part deal including monalizumab in immuno-oncology

Merck KGaA and GlaxoSmithKline for M7824 (bintrafusp alfa) in difficult-to-treat cancers

Oxford Biomedica and Axovant Sciences for OXB-102 in Parkinson's disease

PellePharm and LEO Pharma for patidegib topical gel in Gorlin syndrome

Best Partnership Alliance

Allogene Therapeutics and Pfizer for CAR-T assets 

BenevolentAI and AstraZeneca’s Artificial Intelligence partnership in chronic kidney disease and idiopathic pulmonary fibrosis

Cancer Research UK, LifeArc and Ono Pharmaceutical Cancer Immunotherapy Alliance 

Microbiotica and Genentech (Roche) in inflammatory bowel disease 

Mission Therapeutics with AbbVie for DUB inhibitors for Alzheimer's and Parkinson's diseases 

23andMe and GlaxoSmithKline for the use of genetics to improve R&D success rates  

Business Development Team of the Year

AstraZeneca’s Business Development Operations Team

BeiGene Business Development Team

Bristol-Myers Squibb’s Business Development Team

Clinigen’s Corporate Development Team

Procter & Gamble’s Business Development Team

Servier’s Global Business Development and Licensing Team

Executive of the Year - For Large & Medium Cap Companies

David Chang, president, CEO and co-founder of Allogene Therapeutics

Jeff Jonas, CEO of Sage Therapeutics

Siggi Olafsson, CEO of Hikma Pharmaceuticals

Menelas Pangalos, EVP and president, BioPharmaceuticals R&D, AstraZeneca

Andrew Plump, president, research & development of Takeda Pharmaceuticals

Onno van de Stolpe, Founder and CEO of Galapagos

Executive of the Year - For Small Cap & Private Pharma Companies

Ryan Cawood, founder and CEO of OXGENE

John Dawson, CEO of Oxford Biomedica

Hossein A Ghanbari, founder, chairman, and managing director of advanced research for Sensei Biotherapeutics

Kevin Lee, CEO of Bicycle Therapeutics

Amy Schulman, co-founder and chief executive officer of Lyndra Therapeutics

Raman Singh, president & CEO, Mundipharma Asia-Pacific, Latin America, Middle East and Africa

Best Contract Research Organization – Full-Service Providers

CMIC

Covance

ICON

IQVIA

PPD

Worldwide Clinical Trials

Best Contract Research Organization – Specialist Providers

MMS Holdings

Quanticate

Cardinal Health Regulatory Sciences

Metrion Biosciences

RxGen

PharPoint Research

WuXi App Tec’s Biotech Company of the Year Award

Allogene Therapeutics

Achilles Therapeutics

Galapagos

Alnylam Pharmaceuticals

Oxford Biomedica

HOOKIPA Pharma

Calliditas Therapeutics


Syneos Health’s Best New Drug Award

Alnylam Pharmaceuticals’ Onpattro (patisiran) for polyneuropathy of hereditary transthyretin-mediated amyloidosis

Astex/Janssen Pharmaceutica’s Balversa (erdafitinib) for metastatic urothelial carcinoma

AveXis/Novartis’s Zolgensma (onasemnogene abeparvovec-xioi) for spinal muscular atrophy

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany (cladribine tablets) for multiple sclerosis

Hutchison China MediTech/Lilly’s Elunate Capsules (fruquintinib) for colorectal cancer

Insmed’s Arikayce (amikacin liposome inhalation suspension) for Mycobacterium avium complex lung disease

Sobi’s Gamifant (emapalumab-lzsg) for primary hemophagocytic lymphohistiocytosis